BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved February 12, 2026, awarding 76,701 restricted stock units to 34 new employees.

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved February 12, 2026, awarding 76,701 restricted stock units to 34 new employees.

One-fourth of each employee grant vests on February 16, 2027, then one-twelfth of the remainder vests quarterly thereafter, subject to continued employment. Grants were made under the company's Plan and Nasdaq Listing Rule 5635(c)(4).

Argus Feb 18 session

-2.53% close to close Open Argus

Details

News Market Reaction – BBIO

In the Feb 18 session, BBIO declined 2.53%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine inducement equity grants under Nasdaq Listing Rule 5635(c)(4), awa...

Analysis

This announcement details routine inducement equity grants under Nasdaq Listing Rule 5635(c)(4), awarding 76,701 RSU-based shares to 34 new employees with a standard cliff-and-quarterly vesting schedule. It follows similar RSU grants disclosed in January under the same plan, originally adopted in 2019 and amended in 2023. In context with recent major clinical and financing events, this filing mainly signals ongoing hiring and compensation practices rather than a new fundamental catalyst.

Key Figures

New employees: 34 employees RSU share total: 76,701 shares Initial vesting date: February 16, 2027 +3 more

New employees

34 employees

Inducement RSU grants approved February 12, 2026

RSU share total

76,701 shares

Aggregate common stock underlying new inducement RSUs

Initial vesting date

February 16, 2027

One-fourth of each employee’s RSUs vest on this date

Quarterly vesting schedule

One-twelfth per quarter

Remaining RSUs vest quarterly after initial cliff, subject to employment

Plan adoption date

November 2019

Original adoption of the inducement equity plan

Plan amendment dates

February 10, 2023 and December 13, 2023

Subsequent amendments and restatements of the plan

Historical Context

5 past events · Latest: Feb 12

5 events

1. Feb 12

   Phase 3 results

   24h Move

   +3.7%

   Positive PROPEL 3 topline data for oral infigratinib in achondroplasia.

2. Jan 27

   Inducement grants

   24h Move

   -0.5%

   Inducement RSU grants totaling 31,428 units for 11 new employees.

3. Jan 27

   Inducement grants

   24h Move

   -0.5%

   Inducement RSU grants totaling 34,199 units for 12 new employees.

4. Jan 16

   Convertible notes pricing

   24h Move

   +0.0%

   Pricing of $550M 0.75% convertible notes due 2033 with prefunding use.

5. Jan 14

   Convertible notes plan

   24h Move

   -2.1%

   Proposed $550M 2033 convertible notes to manage 2027 convertible debt.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"approved equity grants to 34 new employees in restricted stock units for an aggregate"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"awards were each granted as an inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on February 12, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 34 new employees in restricted stock units for an aggregate of 76,701 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on February 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio (BBIO) announce about inducement grants on February 12, 2026?

BridgeBio approved equity grants totaling 76,701 restricted stock units to 34 new employees. According to the company, the grants were made as inducements under Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the terms of the Plan.

How do the BridgeBio (BBIO) restricted stock unit vesting terms work?

Each RSU vests 25% on February 16, 2027, then one-twelfth of the remaining shares vests quarterly. According to the company, all vesting is contingent on continued employment on each vesting date.

How many employees received inducement RSUs from BridgeBio (BBIO) and when were they approved?

The compensation committee approved RSUs for 34 new employees on February 12, 2026. According to the company, the awards were granted as material inducements for those employees to join BridgeBio.

Under which plan and Nasdaq rule were BridgeBio's (BBIO) February 2026 grants made?

The awards were granted under BridgeBio's equity Plan and Nasdaq Listing Rule 5635(c)(4). According to the company, the Plan was adopted in November 2019 and amended in 2023.

What is the aggregate size of the inducement grants BridgeBio (BBIO) reported?

The aggregate award equals 76,701 shares in restricted stock units granted to new hires. According to the company, these RSUs were approved by the compensation committee on February 12, 2026.

Do BridgeBio's (BBIO) inducement RSUs require continued employment to vest?

Yes. Vesting is conditioned on continued employment with the company or its subsidiaries on each vesting date. According to the company, that requirement applies to the initial and subsequent vesting tranches.